Table 1.

Patients with stage 1B2 cervical cancer who completed neoadjuvant chemotherapy followed by vaginal radical trachelectomy and pelvic lymph node dissection

Patient	Age, yr	Histology	Grade	Invasion depth, mm	Tumor size, mm	Lymph nodes	LVSI	Cycles of NACT	Path response to NACT	Recurrence	Treatment recurrence	DFS, months	OS, months	Current status
1	28	SCC	3	5	37	0/19	No	6/6	Partial	No	n/a	109.8	109.8	NED
2	30	SCC	1	6	25	0/12	Yes	5/6	Partial	Yes	Surgery + CRT	105.7	110.8	NED
3	24	SCC	3	5	35	0/19	Yes	4/6	Complete	No	n/a	103.5	103.5	NED
4	30	SCC	2	5	20	0/14	No	2/6	Partial	No	n/a	100.3	100.3	NED
5	29	SCC	3	5	35	0/23	No	6/6	Complete	No	n/a	51.4	51.4	NED
6	25	SCC	2	8	30	0/20	Yes	6/6	Complete	No	n/a	52.0	52.0	NED
7	36	AC	3	6	38	0/19	Yes	6/6	Partial	Yes	Surgery + CT + HPV16 vaccine	23.6	67.5	Palliative care
8	30	ASC	2	6	35	0/31	Yes	6/6	Partial	yes	CRT	18.1	32.7	NED
9	29	AC	2	15	28	0/43	No	6/6	Partial	No	n/a	48.1	48.1	NED
10	31	SCC	3	5	20	0/16	Yes	6/6	Complete	No	n/a	12.4	12.4	NED
11	23	SCC	3	4	20	0/18	Yes	6/6	Complete	No	n/a	37.1	37.1	NED
12	25	SCC	2	5	36	0/28	No	6/6	Complete	No	n/a	29.2	29.2	NED
13	31	AC	1	7	35	0/19	No	6/6	Partial	No	n/a	19.3	19.3	NED
14	30	SCC	3	6	40	0/11	Yes	6/6	Partial	No	n/a	11.4	11.4	NED

All patients had stage IB2 and received cisplatin/carboplatin and paclitaxel (70 mg/m²) as NACT.

Abbreviations: AC, adenocarcinoma; ASC, adenosquamous carcinoma; CRT, chemoradiation; CT, chemotherapy; DFS, disease‐free survival; HPV16, human papillomavirus 16; LVSI, lymph vascular space invasion; n/a, not applicable; NACT, neoadjuvant chemotherapy; NED, no evidence of disease; OS, overall survival; Path response to NACT, pathological response after surgery; SCC, squamous cell carcinoma.